Industry news

Novosibirsk scientists can now decisively deal with cancerous stem cells

Marchmont Innovation News

Specialists at the Novosibirsk-based Institute of Cytology and Genetics in Siberia have discovered what they call a universal marker for cancerous stem cells, and have developed a method of destroying such cells, which has reportedly led to successful treatment of two different malignant tumors in lab mice. 

European biopharma funding is down 43% so far this year

Cormac Sheridan / BioWorld

Funding for European biopharmaceutical companies is down 43 percent for the first three quarters of 2016 compared with the same period last year, with total equity investment dropping to $2.335 million from $4.119 million.

With St. Pete super-crystal, new drugs could become easier to develop

Marchmont Innovation News

Researchers at St. Petersburg-based ITMO University have put together an optically active nanodimensional super-crystal with unusual architecture that is believed to enable the separation of organic molecules. This is expected to help simplify new drug development technology considerably. The results of the research  have been published in English in Scientific Reports. 

Russian browser to brace your immune system

Marchmont Innovation News

Researchers at the Institute of Bioorganic Chemistry in Moscow have developed a multifunctional browser, designated VDJviz, to process big data derived from modern DNA sequence analysis. The project is expected to step up the development of immunogenomics. The results of the research have been  described in detail in English in BMC Genomics. 

14 October 2016

Biotech IPOs slow in Q3 despite improvement in general markets

Peter Winter / BioWorld

Biotech IPOs were sluggish in the third quarter, with only seven companies successfully completing their offerings on U.S. exchanges, raising a collective $396 million in the process, according to BioWorld analysis. That was 42 percent below the 12 biotech IPOs, raising $1.35 billion in the third quarter last year and 36 percent off the 11 companies completing their offerings in the second quarter this year, raising $564 million. 

Russian researchers develop new multiple sclerosis solution

Marchmont Innovation News

Collaborative researchers at the Institute of Bioorganic Chemistry, St. Petersburg Municipal Multiple Sclerosis Center #31, and two private companies in St. Pete, Pharmasintez and Xenetic, have developed a new form of vaccine to treat multiple sclerosis, one of the deadliest neurodegenerative diseases of autoimmune nature. Results of the effort have been described in  an article  published in English-language Neurotherapeutics. 

Gene therapy could ward off Alzheimer's disease altogether

Amirah Al Idrus / Fierce Medical Device

No currently available treatment can halt or delay the progression of Alzheimer’s disease, but Imperial College London researchers found that gene therapy may be able to prevent its onset altogether, at least in mice.

Understanding Health Risks Improve Your Chances for Good Health

NIH News in Health

Risks are all around us. A nearby sneeze may raise your risk for catching the flu. Obesity boosts the odds you’ll get diabetes. Smoking increases your risk for many cancers. And if you pay attention to news headlines, you may worry that you’re at risk for food poisoning, Zika infection, shark attacks, and more. How can you know which health risks apply to you?

‘OpenTrials’ site launched as a one-stop shop for medicine trial information

Ben Adams / Fierce Biotech

Clinical trial transparency is the name of the game with a new site launched this week aimed at allowing everyone to “locate, match, and share all publicly accessible data and documents” around medicines studies.

IBM Watson, Siemens unite on population health management

Amirah Al Idrus / Fierce Medical Device

IBM Watson ($IBM) and Siemens Healthineers are teaming up on a 5-year alliance in population health management under which they will help health providers bring value-based care to patients with complex and chronic conditions.